Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 202

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 202
---
 a series of warrants to initially acquire up to a certain number
of ordinary shares to the holders of the Existing Notes set forth therein or in the Amendment and Exchange Agreement (the “Exchange
Warrants”)

On August 28, 2024, the Company
consummated the second tranche of its debt financing under the terms of the Securities Purchase Agreement. At the closing of the second
tranche, the Company sold to JAK Opportunities VI LLC (“JAK”) a senior convertible note (the “Note”) in the principal
amount of $500,000.

On November 11, 2024, the
Company consummated the third tranche of its debt financing under the terms of the Securities Purchase Agreement (“SPA”) referenced
in the current report on Form 6-K filed with the United States Securities and Exchange Commission (the “SEC”) on August 16,
2024. The Form 6-K filed with the SEC on August 16, 2024 is incorporated by reference herein. Pursuant to the terms of the SPA, the Company
may elect at the second additional mandatory closing to sell and the institutional investor party to the SPA shall be required to purchases,
subject to certain conditions, an additional note (“Second Additional Mandatory Note”) in the principal amount of $1,500,000,
after the effective date of the Registration Statement (as defined in the SPA). The sale of the Second Additional Mandatory Note resulted
in $1,395,000 of gross proceeds to the company before fees and expenses. The Notes bears an interest rate of 14.75% per annum and may
be adjustable from time to time pursuant to its terms, with maturity at the 4.5 years anniversary of the date of issuance, subject to
extension at the option of the holders in certain circumstances. The Second Additional Note are convertible at any time, at an initial
conversion price of $0.658.

On November. 18, 2024, the
Company entered into a binding term sheet (the “Term Sheet”) with White Lion Capital, LLC, (“White Lion”) a California-based
institutional investor focused on high-growth, early-stage public companies, setting out the principal terms and conditions for a $100
million equity line of credit, expandable to $500 million. Pursuant to the Term Sheet, NewGen will have the option, but not the obligation,
to sell to White Lion up to $100.0 million in shares of common stock over an initial 36